Key result
APOE ε4 allele linked to ~28% higher odds of subjective cognitive decline versus healthy controls.
Why the study?
Alzheimer disease is increasingly conceptualized as a biological and clinical continuum, and this study aimed to assess the prevalence of the APOE epsilon4 allele in individuals with subjective cognitive decline.
What is the prevalence of the APOE ε4 allele in individuals with subjective cognitive decline compared to cognitively normal and mild cognitive impairment populations?
Meta-Analysis
What is the prevalence of the APOE ε4 allele in individuals with subjective cognitive decline compared to cognitively normal and mild cognitive impairment populations?
The prevalence of the APOE ε4 allele in subjective cognitive decline is intermediate between cognitively normal individuals and those with mild cognitive impairment, supporting SCD as an intermediate stage in the Alzheimer's disease continuum.
Answers are grounded in this paper and cite their sources.
Elevated APOE ε4 prevalence signals higher Alzheimer's risk in subjective cognitive decline; reinforces its position as an intermediate stage on the disease continuum.
Background Alzheimer’s disease (AD) is increasingly conceptualised as a biological and clinical continuum that includes Subjective cognitive decline (SCD), mild cognitive impairment (MCI), and overt dementia. We conducted a systematic review and meta-analysis to assess the prevalence of APOE ε4 allele in individuals with SCD. Methods/aims Main databases were searched to identify studies published up to 15 April 2026, plus citation checking. Eligible studies included participants with SCD defined according to standardized criteria, with available APOE genotype data. Application of SCD- plus criteria was also recorded. Results Of 474 screened records, 49 studies were included in the quantitative synthesis. The pooled prevalence of APOE ε4 allele carriers was 28.3% (95% CI 25.1–31.8%) in SCD, 41.0% (95% CI 35.3–46.8%) in MCI, and 22.0% (95% CI 18.6–25.9%) in cognitively normal (CN) individuals. Multivariate analysis showed that the odds of being an APOE ε4 allele carrier were significantly higher in SCD compared to HC (OR = 1.28, 95% CI 1.12–1.46, p <0.001) and higher in MCI compared to SCD (OR = 1.48, 95% CI 1.23–1.76, p <0.0001). Meta-regression analyses indicated that age and education contributed to heterogeneity in SCD cohorts, while sex distribution did not. Sensitivity analyses restricted to SCD- plus studies confirmed the robustness of these findings. Conclusion The prevalence of APOE ε4 allele in SCD falls between that observed in CN and MCI populations, supporting its role as an intermediate stage in the AD continuum. However, substantial heterogeneity persists, highlighting the need for more accurate stratification approaches integrating genetic and clinical markers.
No takes yet. Share an insight, caveat, or question.
Alonge et al. (2026) conducted a meta-analysis in Subjective cognitive decline. APOE ε4 allele vs. Cognitively normal individuals (healthy controls) was evaluated on Prevalence of APOE ε4 allele carriers (OR 1.28, 95% CI 1.12-1.46, p=<0.001). The APOE ε4 allele was more prevalent in individuals with subjective cognitive decline compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: